"We are pleased to be presenting preclinical data during this year's
Details of the late breaker poster presentation are as follows and will be available for download at the time of presentation at http://regulusrx.com/publications.
Poster Board #LBP-40
Title: "Development of Oligonucleotide-Based miR-132 Antagonists for the Treatment of NASH", Papazyan, R., et al.
Session: Late Breaker Poster session, NAFLD therapy
Poster display date and time:
- Demonstration of miR-132 upregulation (2 to 4-fold) in liver tissues of NASH patients compared to those of healthy donors.
- Demonstration of efficacy in preclinical models of NASH with the Company's lead anti-miR-132. Results showed reduced liver triglyceride levels by up to 50%, neutralized serum liver enzyme levels (ALT and AST), enhanced glucose tolerance, and improved histopathological scores. Therapeutic effects were sustained for up to 6 weeks following the final dose.
- Global gene expression profiling revealed significant increase in metabolic genes and a decrease in inflammatory and fibrotic genes.
Nonalcoholic steatohepatitis (NASH) is an inflammatory liver disease associated with excessive fat accumulation in the liver which can lead to progressive fibrosis. The prevalence of NASH in
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Regulus to undertake certain activities and accomplish certain goals and objectives (including with respect to development and other activities related to its miR-132 program in NASH). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Regulus' financial position and programs are described in additional detail in Regulus filings with the
View original content to download multimedia:http://www.prnewswire.com/news-releases/regulus-to-present-preclinical-efficacy-data-highlighting-potential-of-novel-treatment-for-nonalcoholic-steatohepatitis-at-the-international-liver-congress-2019-300825712.html
Dan Chevallard, Chief Financial Officer, 858-202-6376, email@example.com